Navigation Links
BioMS Medical Announces Second Quarter 2008 Results
Date:8/12/2008

nt of SPMS. Enrollment for the randomized, double-blind study was initiated in June, 2007 and on July 31, 2008, BioMS completed full recruitment of approximately 510 patients at 68 sites across the U.S. To date, the DSMB has conducted two reviews of the data from this trial and has recommended it continue.

(x) MINDSET-01: A phase II clinical trial evaluating MBP8298 (dirucotide) for the treatment of relapsing-remitting MS (RRMS). The randomized, double-blind study has completed recruitment with 218 patients enrolled at 24 trial sites in six countries across Europe. The DSMB has completed five safety reviews to date and recommended that the trial continue as per the protocol. Completion of the trial is expected at the end of 2008 with results anticipated in the first half of 2009.

Licensing and Development Agreement

On December 17, 2007, BioMS entered into a licensing and development agreement granting Eli Lilly and Company exclusive worldwide rights to MBP8298 (dirucotide). Under the terms of the agreement, Lilly and BioMS will collaborate on the development of MBP8298 (dirucotide) and will also share in certain development costs with Lilly being responsible for future research and development, manufacturing and marketing activities. The transaction closed on January 25, 2008 with the receipt of an upfront payment of US$87 million. BioMS has the potential to receive additional development and sales milestones of up to US $410 million and escalating royalties on sales commensurate with the current stage of development of the product if MBP8298 (dirucotide) is commercialized.

Financial Results

The consolidated net loss for the three months ended June 30, 2008 was $0.4 million or ($0.00) per share compared to a consolidated net loss of $11.8 million or ($0.14) per share for the three months ended June 30, 2007. The consolidated net loss for the six months ended June 30, 2008 was $7.1 million or ($0.08) per share compared to a consolid
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. BioMS Medical announces its intention to renew a normal course issuer bid
2. BioMS Medical to present at BioContact 2007
3. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
4. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
5. BioMS Medical announces third quarter 2007 results
6. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
7. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
9. BioMS Medical to present at BIO CEO & Investor Conference
10. BioMS Medical Announces 2007 Year End Results
11. BioMS Medical to present at BioCentury Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... -- China Cord Blood Corporation (NYSE: CO ) ... results for the first quarter of fiscal year 2015 ... the US.  The Company will host ... August 29, 2014 to discuss its financial performance and ... followed by a question and answer session.  Interested parties ...
(Date:8/21/2014)... Gallus BioPharmaceuticals , LLC, ... manufacturing organization (CMO) announced today that it has ... company focused on the development of innovative approaches ... anti-prostate specific membrane antigen (PSMA) monoclonal antibody used ... the agreement the antibody will be produced in ...
(Date:8/20/2014)... of patented university inventions licensed to biotechnology firms ... commercialization. To open these roadblocks, the researchers suggest ... the discovery stage could lead to faster commercialization ... derived from discoveries made in university laboratories and ... during clinical trials, which have a high failure ...
(Date:8/20/2014)... 2014 High performance computing (HPC) ... most complete climate and Earth system model to ... issues. , Eight national laboratories, including Lawrence ... Center for Atmospheric Research, four academic institutions and ... participating national laboratories include Argonne, Brookhaven, Lawrence Berkeley, ...
Breaking Biology Technology:China Cord Blood Corporation to Report First Quarter of Fiscal 2015 Financial Results 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 3Early bottlenecks in developing biopharmaceutical products delay commercialization 2Early bottlenecks in developing biopharmaceutical products delay commercialization 3New Project Is the ACME of Addressing Climate Change 2New Project Is the ACME of Addressing Climate Change 3
... is pleased to announce the,never- before assembly of ... Lighting the Onco-Pipeline -- Innovations in Stem Cell,Biomarker, ... in Tampa,Florida. iiBIG is particularly pleased to join ... Florida, University of Florida, Shands,Cancer Center, Scripps Florida, ...
... Ultra-Fine Beam Shaping Device Optimized for Targeting ... Stereotactic Radiotherapy and Radiosurgery, PALO ALTO, ... (NYSE: VAR ) has received FDA ... (MLC), an ultra-fine beam shaping,device for radiosurgery. ...
... Morria Biopharmaceuticals Plc, a,private biopharmaceutical company ... today that it has,appointed Rosemary Mazanet M.D., ... Mazanet has significant experience in both executive ... Dr. Mazanet serves on the Board of ...
Cached Biology Technology:Lighting the Onco-Pipeline, Stem Cell Cancer, and More at Global Cancer Congress, January 28-29, 2008, Tampa 2Lighting the Onco-Pipeline, Stem Cell Cancer, and More at Global Cancer Congress, January 28-29, 2008, Tampa 3Varian Medical Systems Receives FDA 510(k) Clearance for High-Definition Collimator That Enables Ultra-Fine Intensity-Modulated Radiosurgery 2Varian Medical Systems Receives FDA 510(k) Clearance for High-Definition Collimator That Enables Ultra-Fine Intensity-Modulated Radiosurgery 3Morria Biopharmaceuticals Plc Announces Appointment of Dr. Rosemary Mazanet as Interim Chief Executive Officer 2
(Date:8/21/2014)... the pancreas digesting itself resulting in severe abdominal pain, ... around 20,000 patients are diagnosed with the disease resulting ... treatment is restricted to intravenous fluid and nutritional support. ... Life Sciences, who led the research, said "The major ... stones and excessive alcohol intake combined with a high ...
(Date:8/20/2014)... , Aug. 20, 2014 /CNW/ -  Issue ... and can quickly become life threatening for some children.    ... as 1.2 million Canadians have food allergies and this number ... cent of children are estimated to have food allergies.  ... mild skin irritations and hives to breathing difficulties and loss ...
(Date:8/20/2014)... of Health has awarded the Oklahoma Medical Research Foundation ... on anthrax and the bacteria,s effects on humans. ... and his colleagues have studied the human immune response ... for Human Immunology. The original funding came soon after ... heels of the terrorist attacks of Sept. 11, 2001. ...
Breaking Biology News(10 mins):Insulin offers new hope for the treatment of acute pancreatitis 2Information Update - Allergens and food safety at school - What's in your child's lunch? 2Information Update - Allergens and food safety at school - What's in your child's lunch? 3$14.5 million grant awarded to continue anthrax studies 2
... United States, African Americans have approximately twice the risk ... a similar prevalence in earlier stages of chronic kidney ... (GW) researcher Dominic Raj, M.D., identifies factors that mediate ... black patients and white patients, as well as among ...
... range-wide assessment of the bonobo (formerly known as the ... known and endangered great ape is quickly losing space ... of usable habitat is attributed to both forest fragmentation ... of Georgia, University of Maryland, the Wildlife Conservation Society, ...
... University School of Medicine (BUSM) and Boston Medical Center ... initiative funded by the Bill & Melinda Gates Foundation. ... BMC, and Ducksoo Kim, MD, professor of radiology at ... fellowship at BMC, will use nanotechnology to develop a ...
Cached Biology News:Genetics contribute to increased risk for end-stage renal disease for African Americans with CKD 2Study finds the forgotten ape threatened by human activity and forest loss 2Study finds the forgotten ape threatened by human activity and forest loss 3BUSM/BMC receives Grand Challenges Explorations grant to develop next generation condom 2BUSM/BMC receives Grand Challenges Explorations grant to develop next generation condom 3
... Custom monoclonal antibody development to targets including ... molecules, DNA, and cancer-specific surface antigens. ... and is completed in approximately 40 days ... nature of antigens). Phase I: Immunization, ...
... Clone/PAD: ZMD.460. Immunogen: Synthetic peptide ... human C35 protein (chromosome 17 open reading ... Specific for the C35 protein. On ... at ~15 kDa band. Reactivity: Human ...
... Peptide sequences: Two separate ... corresponding to the same sequence used ... antiserum (Catalog No. 160890) ... with Cayman's guanylate cyclase polyclonal antiserum ...
Immunogen: Secretory component isolated from human colostrum. Storage: 4 C...
Biology Products: